Member Info for TorquayFan

AB and Miavoce - it's been a good discussion and I have enjoyed your ideas.

Just for fun AB, I still believe the science will see us through.

As for strategy, I'd be very surprised if the BoD don't have their ideas quite clear but, no matter how much it's 'planned', what actually happens will be dependent on what approaches Scancell get. The strategy will be the minded direction which may modify as things progress.

A nice weekend to you.

Maybe this is not new, but I like the layout of the new home page https://scancell.co.uk/home IMO a neat and clear listing of the 4 platforms and their targets . . .

Concerns yesterday about Prof. Lindy's CEO/CSO role are understandable as is the current overdose of impatience, in which I share. Of course a case can be made that we are 'underpowered' in the commercial dept., (with all due respect to RG).

My feeling is that we are OK as we are at this stage. It'll surely be a team effort with LD, JC, RG, Martin Diggle, Ursula Ney, Susan Clement-Davies and Redmile, Calculus and Advisors all providing contacts and insights. Commercial drive will ignite when Pharma come calling seriously wanting access to some of Scancell's science. By the look of recent progress, it shouldn't be too long . . . . .

All things are possible of course, but IMO the often mooted concern about a quick/cheap back door deal going through is unlikely to happen. Call me naive, (alright I know), but I just don't see Prof. Lindy and the BoD falling for that or letting the LTH down in that way - they know what they have in this IP.

It's easy to mock this position of course but bear in mind we have received regular good news lately. The current SP is disappointing but we are getting closer all the time to that long awaited 'inflexion point'. GLA

Bermuda thanks for that 'straightener' on the Redmile subject. As before once or twice.
From myself, to those who feel Scancell may be 'sold short', I really don't think that will happen.
IMHO any deal of consequence, will rely on Prof. Lindy's guiding hand AND again IMO, there is no way she is going to sell the science OR the LTH under par in any way. And that is decisive, because she is integral to it, (the science) progress.

Thanks Johnny. I see the report mentions the vaccine as addressing 'Omicron'. No claim to be 'Universal' ? Or to having wider coverage generally . . . .

You can say that again Violin !!! 2 generations ? No chance for me LOL
However much to be happy about and some blue !
A nice walk today from Mullion to Kynance Cove - just perfect. GLA

Chester - thanks for reviving the BioNTech benchmark and that level of optimism, which Burble's post sort of explains as being quite feasible.

After BioNTech's amazing rise, I wonder what they have to follow. With the resources they have at hand, I am amazed that they haven't pursued Scancell with big bucks. Of course BioNTech are a proven force but it defies my imagination to comprehend that they might have a greater science potential in the bag than our little diamond . . . .

MoonP the 'altruism' is often mentioned but I agree, not as the sole reason for having invested.

Re. your second para. I agree but I wonder how IP is to be 'adjusted' ? Isn't that just another way of saying 'shared'. I'm hoping the sharing of IP will only be that necessary for manufacture which is not likely to affect Scancell, (if we ever reach that stage).

I really can't see that this WTO waiver agreement is going to affect us much.

Anyway, a nice blue week. More please . . . .

Roses/AB - I'm not surprised that 'waiver' took 2 years to negotiate ! What a minefield - LOL might they make it retrospective and recover profits from Pfizer/BioNTech, AZ and Moderna etc. ?

Insofaras the researchers working on Gen2 Covid vaccines started their projects under a different set of rules, the WTO intentions are good of course, just totally impracticable. If a way is found to compulsorily share the IP then there are sure to be some interesting Court Cases to follow - recovery of lost profits . . .

Looking at this re. Scancell, because Covidity emerged from Immunobody science under Patent, surely compulsory sharing of IP will be out of the question. For me it's hard to see how this waiver can affect 'us' and I'm not concerned about it. But in this crazy World of 2022, I could be wrong of course.

I agree with other Posters an update on 'Covidity' would be great to see !

In the DT today :-

"" Catching omicron does not protect people from a future infection from the variant, Imperial College has found, as scientists said it explained why cases remain stubbornly high. Throughout the pandemic, studies have shown that a previous infection provides immunity against catching Covid again, as well as often protecting against other variants. But new research has found that there is virtually no extra immunity boost from getting omicron, leaving people at risk of being reinfected from the strain. The study may help explain why cases are continuing to rise, even though huge numbers of people have now been infected with Covid. The latest update from the Government’s coronavirus dashboard from June 9 shows that Covid cases in England rose 64 per cent in the previous week, while hospitalisations increased by 33 per cent.

Professor Danny Altmann, from Imperial’s department of immunology and inflammation, said: "The message is a little bleak. Omicron and its variants are great at breakthrough, but bad at inducing immunity, thus we get reinfections ad nauseam, and a badly depleted workforce." He added: "Not only can it break through vaccine defences, it looks to leave very few of the hallmarks we’d expect on the immune system – it’s more stealthy than previous variants and flies under the radar, so the immune system is unable to remember it." In the latest study, the team sought to find out why so many people have been reinfected with omicron, often quite soon after their initial bout. The team analysed blood samples from UK healthcare workers who received three doses of mRNA vaccine, and who had different infection histories, to investigate antibody, T and B cell immunity.

They found that in people who were triple vaccinated and had no prior infection, an omicron infection provided an immune boost against previous variants such as alpha, beta, gamma, delta and the original ancestral strain, but virtually nothing against Omicron itself. People infected during the first wave of the pandemic and then again with omicron also lacked any immune boosting, an effect the researchers have termed "hybrid immune damping". "" . . . . .

https://www.telegraph.co.uk/news/2022/06/14/catching-omicron-does-not-protect-against-future-infection-variant/

IF Covidity can protect against infection unlike the existing vaccines, then it will surely be a MOST valuable commodity will it not ??

As I post, LSE have still not recorded today's RNS !

It's good to see our great science minds agree and posted thoughts within about 5 minutes.

I confess to having little or no understanding of the science myself and I suspect I am not the only poster in that category. Burble, Inan, Bermuda and many others do these BB's and Scancell a great service in sharing their insights.

So from me a big thanks Guys.

And it's good to see a few things coming together - more please. ATB

Re. 'slow' progress in the RSA with Covidity, (if it is), some interesting words about what the 'Lung Institute' faces :-

"After two years of breakneck research, scientists have amassed a collection of therapies to treat people with COVID-19. But now, researchers fear that development of new treatments could falter as the clinical trials needed to test them become increasingly difficult. Vaccinations in many places have led to a decline in severe disease, shrinking the pool of potential study participants. Hesitance to enrol in trials is rising, and the existence of potent treatments is making statistical analysis more difficult, too.

“It was definitely easier to do research in the past. Now you’ve got to design a study that meets the standards of care, doctors want to do, and patients want to do. And it’s a lot harder,” says Elizabeth Hohmann, an infectious-disease expert at Massachusetts General Hospital in Boston.

https://www.nature.com/articles/d41586-022-01602-5?utm_source=Nature+Briefing&utm_campaign=c9d14a19b3-briefing-dy-20220614&utm_medium=email&utm_term=0_c9dfd39373-c9d14a19b3-46080614

Douve I expect that'll be about 'Dostarlumab' (?) which had some publicity after some good but early data last week? It's a bit early for Modi 1 to be getting publicity for a breakthrough . . . .

But if it's Scancell that would be great !

FPD was great but, we had 3 other Patients lined up on the starting blocks. Good luck to them all.

I see EE over there has already developed the 'reverberate' point that I made too.
Great minds? Maybe in his case LOL.

Here's another posted by EE earlier :-

""Time to repeat a few quotes from professors at last November’s AGM re Modi-1:
“Outstanding data - the best mouse data I have ever seen in my career”
“The trial is a unique opportunity for patients who are newly diagnosed. I’m very excited about the pre-surgery trials in head and neck cancer”
“This has the potential to set up Scancell as an opinion leader”
“Modi-1 is a potential game changer for cancer patients”
“Scancell has the potential to be first-in-class if Modi-1 works”

And it is worth going back to the relevant slides in the AGM and considering the potential speed and scale of the news impact for Scancell in the early months of this trial." ""

Good post I thought. Thanks EE.

Around 9 years in the making . . . .

In the RNS Prof. Lindy is quoted - “We are optimistic about the broad clinical utility of Modi-1 and, following safety assessments in the first few cohorts of patients, we intend to rapidly recruit patients across all four cancers." It's the words 'rapidly recruit' that caught my eye ! I'm surmising that if Modi helps the first Patient the news will reverberate in the inside circles of the trial and 'Rapid' recruitment may actually ensue. Fingers crossed then!

The RNS again - "The Modi-1 peptides are linked to AMPLIVANT®, a potent adjuvant which enhanced the immune response 10-100 fold and resulted in highly efficient tumour clearance, including protection against tumour recurrence, in preclinical models. AMPLIVANT® is the subject of a worldwide licensing and collaboration agreement with ISA Pharmaceuticals for the manufacturing, development and commercialisation of Modi-1." So this is a triumph, potentially, for ISA too!

Well done team Scancell !!

WTP - not to be gloomy, but I'm sure most cases are not being reported these days because the symptoms are generally mild. As a result I suspect the number of formal cases known is an underestimate, a wild one.

Unless a variant with much worse symptoms appears, I'd guess that the vax scene will move to an annual Autumn dosage for Covid, as with the 'flu jab. If Covidity data is good, surely Covidity will be a good candidate for that role . . .

Of course a 4th ? wave is possible, but I think it too early to put the barricades up. AIMO

Thanks Burble. Very much. I'll pop that over there if I may.

Crumbs - dostarlimab news was linked yesterday and Inan replied on the other side, 50861 :-

"However, dostarlimab can only be used on up to a tenth of colorectal cancer patients who have a genetic mutation in their tumour, which all trial participants had. . . . . . just in case anyone thinks that Moditope may be trumped".

Inan bullish as ever, but an interesting point, assuming it's correct.

Just for interest - in the cornea

https://www.nature.com/articles/d41586-022-01578-2